MAGEA3 and cancer: Vaccines against MAGEA3, NY-ESO-1 and PRAME can elicit cancer-specific T cell responses [[25], [26], [27], [28], [29]] implying potentially increased immunogenicity of HNSCC in response to DAC treatment.